As Congress and the administration consider FDA reforms, reorganizing the agency's structure so disease experts work together may be necessary, but former Commissioner Mark McClellan wonders whether the status quo may be the most efficient in some cases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?